Inspired By Nature
Psilocybin has been used for thousands of years for spiritual, cultural, and medicinal purposes. It is not naturally addictive.
There has been a renewed interest in psychedelic drugs as potential therapies for mental health conditions. Recent years have seen significant progress using psilocybin, in both clinical validation and basic research on mechanisms of change. Academic groups in the United Kingdom (Imperial College; Carhart-Harris et al., 2018;2021) and the United States (Johns Hopkins; Griffiths et al. 2016; Johnson et al., 2014) have shown promising results in studies of synthetic psilocybin-assisted therapy on treatment-resistant depression, post-traumatic stress disorder, and addictions. Regulatory frameworks are more open to approving studies—psilocybin recently received FDA Breakthrough approval for treating severe treatment-resistant depression and major depressive disorder.
Though the first results from clinical research are promising, ample work still needs to be done before final conclusions can be drawn on the safety and effectiveness of psilocybin-assisted therapies. Additionally, there is a lack of development and validation of approaches aimed at optimizing treatment delivery. The topics of psychological interventions that support drug administration before, during, and after sessions and the measurement of treatment effects with neural and physiological data both require more research and development.
Zylorion has established agreements with companies dealing with the full spectrum of drug development—including production, extraction, and manufacturing—in the United States, Canada, and the Netherlands. All production will be carried out under the highest Good Manufacturing Practice (GMP) standards.